A biopharmaceutical company, which develops novel gene-based therapeutic drugs and vaccines.


Updates from The Motley Fool

Latest updates on GenVec from Fool.com.
GenVec Q4 Net Loss Deepens

The pharmaceutical company lands firmly in the red, but the net result isn't as bad as expected.



Stock Performance

View Interactive GNVC Charts
Sponsored by

Key Data Points

Primary metrics and data points about GenVec.
Current Price: $6.78
Prev Close: $7.00
Open: $6.93
Bid: $6.70
Ask: $6.77
Day's Range: $6.78 - $6.95
52wk Range: $2.70 - $14.00
Volume: 25,879
Avg Vol 889,192
Market Cap: $15M
P/E (ttm): -2.33
EPS (ttm): ($3.00)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about GenVec.
CAPS Rating 1 out of 5
 
261 Outperform
28 Underperform
CAPS All Stars
 
37 Outperform
17 Underperform

How do you think GenVec will perform against the market?



You pick for GenVec is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Paul H. Fischer, CEO

31% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for GenVec.

A biopharmaceutical company, which develops novel gene-based therapeutic drugs and vaccines.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers